Comparative effects of enoximone and theophylline on plasma catecholamines and haemodynamics in cardiosurgical patients

Summary The release of endogenous catecholamines in aorto-coronary bypass graft patients receiving either 0.5 mg/kg enoximone (n=10), 4.0 mg/kg theophylline (n=10) or saline solution (control,n=10) has been studied, as well as certain haemodynamic parameters. Adrenaline (A) and noradrenaline (NA) concentrations were not significantly changed by the administration of enoximone. Theophylline caused a small increase in NA (+ 40% in the 1st min) and a marked increase in A (approximately + 7000% in the 1st min), which still remained elevated at the end of the investigation period (+ 220% in the 30th min). The major haemodynamic effects of enoximone were a significant increase in cardiac index (CI; + 35%) and a decrease in pulmonary capillary wedge pressure (PCWP; −27%), pulmonary artery pressure (PAP; −21%), RVEDV and RVESV, while the heart rate (HR) remained almost unchanged. The dominant haemodynamic effects of theophylline were an increase in HR (+ 26%; arrhythmia in 3 patients), PAP (+ 22%), and RVEDV (+ 19%), while REVESV (+ 26%), MAP (−16%), CI (−14%), and RVEF (−15%) fell significantly. It is concluded that the haemodynamic actions of enoximone are not mediated by catecholamine release, whereas the adverse cardiovascular effects of theophylline might partly be explained by the significant increase in plasma adrenaline.     

How adverse drug reactions can play a role in innovative drug research

We describe how adverse drug reactions (ADRs) can play an important role in pharmaceutical research and drug development. Not only do ADRs represent the risks and drawbacks associated with drugs but they can also be related to other knowledge available in pharmaceutical and medical research. We offer a model that can be used to systematically map the pathways through which ADRs can lead to innovative research. These pathways include chemical, therapeutic or pathophysiological steps that can be taken to arrive at new knowledge based on ADRs. We used the development of angiotensin-converting enzyme inhibitors, especially captopril, as a case study. The similarity between the ADR profiles of captopril and penicillamine was a starting point for further innovation. Historical analysis shows that in several instances research in the field of angiotensin-converting enzyme inhibitors has been triggered by ADRs. The model presented here might be applicable to other areas of innovative drug research.     

Duchenne型肌营养不良症

作者综述了１０年来对Ｄｕｃｈｅｎｎｅ型肌营养不良症（ＤＭＤ）的研究概况。主要包括①ＤＭＤ的临床研究。②血清生化研究表明ＣＫ、ＬＤＨ、Ｍｂ是诊断ＤＭＤ病人和携带者的敏感指标。③心脏无创性检测和肌肉超微结构研究。④部分抗肌萎缩蛋白基因ＹＡＣ物理图谱，精细限制酶图谱和缺失热区的核苷酸顺序分析，首次发现内含子中ＡＴ富集区的同源顺序与ＤＭＤ断裂有关。⑤抗肌萎缩蛋白的缺失热区疏水肽段存在与否与ＤＭＤ发病密切相关。     

悦您定对原发性高血压患者长期与即刻疗效的观察

观察了悦您定治疗６０例原发性高血压患者的长期疗效，２０例原发性高血压患者的即刻疗效，及用药过程中的个体反应。长期疗效与即刻疗效分析均有明显统计学意义（Ｐ＜０．０１）。两组患者，经临床与相应实验室检查均未发现肝、肾、血液系统伤害性副作用。     

正常人及大鼠心脏内皮素转换酶的分布

目的:了解正常人和大鼠心脏各部分内皮素转换酶(Endothelin-conveerting en-zyme,ECE)的分布。方法:采用半定量RT-PCR法检测ECE mRNA表达,同时根据外源性的巨内皮素-1转变为内皮素-1的量判定ECE活性。结果:正常人心脏各部位心肌均存在ECE,ECEmRNA表达和活性的分布特点一致:心房显著高于心室,左、右心房间及左、右心室和室间隔间无显著性差异。大鼠的ECE mRNA表达和活性分布规律与人相似。结论:正常人和大鼠心脏各组分均存在ECE,且两者的分布规律相似。     

尖吻蝮蛇毒引起类DIC病因的研究

本文借助 DEAE-sephadex A-50和 Sephadex G-75柱层析从尖吻蝮蛇毒(AAV)内分离并纯化出一种类凝血酶(TLE).这种 TLE 以1.5U/Kg 体重注入麻醉狗的静脉后,观察到血凝筛选试验 Fgn、BPC、PT、TT 和血清 FDP 全部异常;但凝血因子Ⅱ(Quick 二期法)、AT-Ⅲ以及纤维结合蚤白(Fn)含量仍在正常范围内.这提示实验狗血循环内未有凝血酶形成的证据,从而说明 AAV-TLE是 AAV 中毒患者并发类 DIC 综合征的主要病因.     

Aromatase and its inhibitors in breast cancer treatment — overview and perspective

Summary Estrogen has an important role in stimulating the growth of breast carcinomas. Inhibition of estrogen production is therefore a logical treatment strategy. A number of selective inhibitors have been developed against aromatase, a cytochrome P-450 enzyme which catalyzes the rate limiting step in the biosynthesis of estrogens. The mechanisms of the aromatase reaction, current knowledge of the enzyme, and regulation of its expression are discussed as the basis for inhibitor development. Two classes of aromatase inhibitors, steroidal and non-steroidal compounds, are now coming into use. Among the steroid substrate analogues, 4-hydroxyandrostenedione (4-OHA) has been shown to be effective in breast cancer patients with advanced disease and was recently approved for treatment in the United Kingdom. Several different classes of compounds which act as aromatase inhibitors are currently in clinical trials and should provide breast cancer patients with a number of treatment options. Among these are highly potent and selective non-steroidal inhibitors which have recently been found to suppress plasma and urinary estrogens over 95% in breast cancer patients. The potency of these newer aromatase inhibitors provides the opportunity to determine whether complete suppression of estrogen production and action will result in enhanced tumor regression.     

复合酶中糖化酶活力的测定

复合糖化酶的酶活力检测是主要的质量控制指标,只有选用合理的糖化酶活力检测方法,才能真实反映出复合酶中糖化酶活力的高低.为避免因协同作用而产生的复合酶中其他酶制剂对糖化酶活力检测的干扰,作者总结了以往的研究成果,结合4种不同酶制剂的作用机理,最终否定了常用的淀粉底物法,确定了麦芽糖底物法为首选方法.